Home » Topics » Regulatory

Regulatory
RSS

ESI Lederle launches generic acyclovir

April 29, 1997

FDA approves new labeling for Bristol-Myers Squibb's Pravachol

April 29, 1997

Mylan Laboratories's Acyclovir receives FDA approval

April 25, 1997

Final FDA approval for Faulding's acyclovir injection

April 24, 1997

IVAX presents promising preclinical results with Elmiron

April 22, 1997

Teva receives FDA approval for antihypertensive generic

April 22, 1997

U.K. approval for Edronax

April 21, 1997

Imitrex Nasal Spray introduced in Canada

April 21, 1997

Royce Laboratories' generic antiinflammatory approved by FDA

April 18, 1997

Biovail's Tiazac approved and introduced in Canada

April 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...